Citius Pharmaceuticals, Inc. (CTXR)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 3.9M | 1.7M | 1.5M |
| Gross Profit | 3.2M | 1.3M | 1.0M | |
| Operating Income | (8.4M) | (9.0M) | (32.2M) | (10.0M) |
| Net Income | (8.0M) | (8.2M) | (21.2M) | (8.9M) |
| Diluted EPS | N/A | $-0.38 | $-0.95 | $-0.34 |
Annual Financials
| Metric | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (33.3M) | (36.7M) | (42.0M) | (38.5M) |
| Net Income | (33.6M) | (32.5M) | (39.1M) | (37.4M) |
| Diluted EPS | $-5.75 | $-5.57 | $-5.97 | $-3.38 |